1.1 The case for adopting ENDURALIFE‑powered cardiac resynchronisation therapy-defibrillator (CRT‑D) devices for treating heart failure is supported by the published evidence. Extended battery life is of clinical and patient benefit and associated with fewer replacement procedures.
1.2 ENDURALIFE‑powered CRT‑Ds should be considered as an option in people offered CRT‑D devices in line with NICE technology appraisal guidance on implantable cardioverter defibrillators and cardiac resynchronisation therapy.
1.3 Cost modelling was based on published data using predecessor devices, and showed that the price and lifespan of the CRT‑D have the greatest effect on overall treatment costs. Assuming an average selling price of £12,404 across different devices, using ENDURALIFE‑powered CRT‑Ds may save between £2,120 and £5,627 per patient over 15 years through a reduction in the need for replacement procedures. This could save the NHS in England around £6 million in the first 5 years.